Overview of the lipid formulations of amphotericin B

Journal of Antimicrobial Chemotherapy

Volumn 49, Issue SUPL. S1, 2002, Pages 31-36

  Dupont, Bertrand ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; LIPOSOME;

AREA UNDER THE CURVE; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BRAIN LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG COST; DRUG DIFFUSION; DRUG EFFICACY; DRUG FORMULATION; DRUG INFUSION; DRUG SAFETY; FUNGAL MENINGITIS; FUSARIUM; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; MYCOSIS; NEUTROPENIA; PRESCRIPTION; PYREXIA IDIOPATHICA; RANDOMIZED CONTROLLED TRIAL; RETICULOENDOTHELIAL SYSTEM; ZYGOMYCETES;

EID: 0036178458     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/49.suppl_1.31     Document Type: Article

References (20)

1. Aspergillus and Candida infections in bone marrow transplantation: Progress and controversies
2. Amphotericin B: 30 years of clinical experience
3. Pretreatment regimens for adverse events related to infusion of amphotericin B
4. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis
5. Amphotericin B in children with malignant disease: A comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion
6. Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients
7. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system
8. A randomized double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia
9. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients
10. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia
11. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
12. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections
13. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis
14. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis
15. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis
16. Amphotericin B lipid complex (ABLC) versus amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis
17. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases
18. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections
19. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis